Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Melanoma 1Leukemia, Promyelocytic, Acute 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

fludarabine phosphate 21Cyclophosphamide 20Peripheral Blood Stem Cell Transplantation 19Busulfan 16Tacrolimus 14Whole-Body Irradiation 12Methotrexate 12Mycophenolic Acid 11Cyclosporine 11Antilymphocyte Serum 10fludarabine 6Filgrastim 6peginterferon alfa-2a 5ruxolitinib 4Radiotherapy 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Decitabine 4Aspirin 4Stem Cell Transplantation 3Injections 3Cytogenetic Analysis 3Cytarabine 3Biopsy 3Azacitidine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3merphos 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thrombocythemia, Essential × arsenous acid × Clear all
NCT01014546 2022-07-22

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Roswell Park Cancer Institute

Phase 1 Terminated
5 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡